<DOC>
	<DOCNO>NCT01835964</DOCNO>
	<brief_summary>The purpose study investigate blood sugar change response insulin body counter-act low blood sugar people Type 1 Diabetes Mellitus . Insulin sensitivity term use describe blood sugar change within body response insulin . Greater understanding insulin sensitivity , particularly body respond low blood sugar , help u good predict blood sugar level change . All subject receive liquid mixed-meal blood sugar response monitor order study insulin sensitivity . All subject receive additional insulin injection give cause low blood sugar order understand body respond low blood sugar . All subject closely monitor time insulin give , frequent check blood sugar constant medical nursing supervision . Details visit , test procedure describe . During study , study team ask subject use insulin pump glucometer . Subjects need use glucometer entire study . Subjects provide 1 box strip . Subjects require use lispro ( Humalog ) insulin 2-3 day inpatient admission provide free charge .</brief_summary>
	<brief_title>Biobehavioral Mechanisms Glucose Variability</brief_title>
	<detailed_description>Glucose variability ( GV ) type 1 diabetes ( T1DM ) increasingly view primary marker glycemic control , responsible , along chronic hyperglycemia reflect HbA1c , diabetes complication . In study , propose investigate : ( ) time course deterioration physiological glucoregulatory mechanism lead increased GV , ( ii ) association GV metabolic behavioral factor insulin sensitivity treatment adequacy . Our primary hypothesis : Glucose variability T1DM trigger behavioral event ( e.g . meal , insulin injection , exercise ) challenge metabolic system . The timing magnitude behavioral challenge , ability metabolic mechanism absorb challenge , determine magnitude GV . This process develop certain time frame , accelerated inadequate treatment , attenuate precise timing dose bio-behavioral control . This study use combination treatment record , continuous glucose monitoring ( CGM ) , inpatient admission clarify relationship behavioral challenge metabolic system , physiological glucoregulatory mechanism , GV . This study test follow hypothesis : 1 . Suboptimal treatment behavior , e.g . insulin mistiming ( early/late meal insulin ) unbalance insulin ( high basal/bolus ratio ) , correlate high GV repeat hypo- hyperglycemia ; relationship mediate patient ' insulin sensitivity ; 2 . A metabolic challenge ( e.g . consecutive sequence hypo- hyperglycemia ) , push metabolic system transient super-critical state characterize increased GV define Variability Grid Analysis ( VGA ) Average Daily Risk Range ( ADRR ) , persist several day beyond discontinuation challenge .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Clinical diagnosis type 1 diabetes mellitus ≥2 year . For individual enrol least one criterion list must meet . Criteria document hyperglycemia ( least 1 must meet ) : Fasting Blood Glucose ( BG ) ≥126 mg/dL 2h Oral Glucose Tolerance Test ( OGTT ) ≥200 mg/dL Hemoglobin ( HbA1c ) ≥6.5 % BG ≥200 mg/dL symptom History hyperglycemia consistent diabetes Criteria require insulin diagnosis ( 1 must meet ) : require insulin diagnosis continually thereafter insulin diagnosis upon investigator review likely need insulin ( significant hyperglycemia respond oral agent ) insulin eventually require use continually insulin diagnosis continue hyperglycemia , positive islet cell antibody consistent latent autoimmune diabetes adult ( LADA ) insulin eventually require use continually Use insulin pump least six month prior study . Using bolus calculator predefined parameter carbohydrate ratio ( ) , insulin sensitivity factor ( ) . Signed informed consent . Age ≥21 &lt; 65 year old . HbA1c ≤10 % measure DCA 2000 equivalent device . Willingness use lispro ( Humalog ) insulin metabolic challenge admission . Willingness perform selfmonitoring blood glucose ( SMBG ) &gt; 4 times/day . Willingness avoid consumption acetaminophencontaining product study . Willingness perform 4 day outpatient assessment time , prepackaged meal snack , &gt; 7 SMBGs . Uncontrolled arterial hypertension ( rest blood pressure &gt; 160/100 mm Hg ) . Impaired hepatic function measure alanine aminotransferase aspartate aminotransferase ≥3 time upper reference limit . Impaired renal function : glomerular filtration rate ( calc GFR ) &lt; 60 ml/min/1.73 m2 . Diabetic ketoacidosis past 6 month Conditions may increase risk induced hypoglycemia : uncontrolled coronary artery disease stable unstable angina episode chest pain cardiac etiology document Electrocardiography change positive troponin level positive stress test catheterization coronary blockage &gt; 50 % congestive heart failure significant cardiac arrhythmia history cerebrovascular event seizure disorder syncope adrenal insufficiency hypoglycemiainduced migraine within past year neurological disease Diabetic complication alter insulin kinetics food absorption Pregnancy , breastfeed intention become pregnant . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation . Psychiatric disorder would interfere study task ( e.g . inpatient psychiatric treatment within 6 month prior enrollment ) . skin condition prevents sensor placement abdomen arm . Difficulties operate Continuous Glucose Monitor . Uncontrolled thyroid disease : thyroidstimulating hormone ( TSH ) &gt; 10 . Bleeding diathesis dyscrasia . Alcohol drug abuse within 1 year enrollment patient history . Allergy component CGM sensor . Blood donation &gt; 473 ml last 56 day Prior noncompliance study procedure . Hematocrit outside normal range . Magnesium &lt; 1.6 mg/dl . Potassium &lt; 3.4 mmol/L . Active enrollment another clinical trial Allergy intolerance insulin lispro ( Humalog ) Anticoagulant therapy aspirin . Oral steroid . Use acetaminophencontaining medication . Use Type 2 Diabetes Mellitus medication : include metformin , sulfonylurea , meglitinides , thiazolidinediones , Dipeptidyl peptidase4 ( DPPIV ) inhibitor , glucagonlike Peptide ( GLP1 ) agonists alphaglucosidase inhibitor . Unwillingness withhold Pramlintide duration study intervention .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Glucose Variability ( GV )</keyword>
	<keyword>Continuous Glucose Monitor ( CGM )</keyword>
</DOC>